BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27032646)

  • 1. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
    Thanarajasingam G; Bennani-Baiti N; Thompson CA
    Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Karls S; Shah H; Jacene H
    Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
    Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
    Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
    El-Galaly TC; Hutchings M
    Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
    Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
    [No Abstract]   [Full Text] [Related]  

  • 8. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
    Paksi M; Demeter J; Szabó P
    Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.
    Kobe C; Dietlein M; Hellwig D
    Semin Nucl Med; 2018 Jan; 48(1):28-36. PubMed ID: 29195615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PET in lymphoma.
    Schwaiger M; Wieder H
    Chang Gung Med J; 2005 May; 28(5):315-25. PubMed ID: 16086546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
    Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
    Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
    Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
    PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of contrast-enhanced ultrasound and PET/CT in assessment of extramedullary lymphoma.
    Jiang W; Xue H; Wang Q; Zhang X; Wang Z; Zhao C
    Eur J Radiol; 2018 Feb; 99():88-93. PubMed ID: 29362156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.